Synaptic Dysfunction

Gate Neurosciences is developing a new portfolio of next-generation therapeutics to treat synaptic dysfunction in patients with central nervous system disorders, the company announced in a press release.

Researchers have found lower levels of a protein associated with neural connections in the living brains of people with schizophrenia, according to results of parallel clinical and preclinical studies published in Nature Communications.